Format

Send to

Choose Destination
Iran J Immunol. 2013 Mar;10(1):10-21. doi: IJIv10i1A2.

Sclareol reduces CD4+ CD25+ FoxP3+ Treg cells in a breast cancer model in vivo.

Author information

1
Department of Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran, shnoori@sbmu.ac.ir.

Abstract

BACKGROUND:

Sclareol is a phytochemical used in people's diet in Southeast Asia.

OBJECTIVE:

To investigate the immunotherapeutic effectiveness of Sclareol against breast cancer by direct intraperitoneal injection.

METHODS:

Sclareol was isolated and purified from Salvia sclarea. Effect of Sclareol on cell growth inhibition was evaluated by MTT assay. Intraperitoneally injected Sclareol effects on reducing the tumor volume and shifting the cytokine profile were investigated. We also assessed if intraperitoneally injected Sclareol could improve the outcome of cancer therapy through suppressing the regulatory T cells.

RESULTS:

The results confirmed a significant decrease in the tumor size. Furthermore, a significant decrease in the level of IL-4 and an increase in the level of IFN-γ were noticed in the intraperitoneally injected Sclareol group (p<0.05). It was also observed that the splenocytes of treated animals significantly increase in cell proliferation assay. Moreover, measurements of splenic T regulatory cell indicated that intraperitoneally injected Sclareol significantly decreased the number of splenic T regulatory cell.

CONCLUSION:

Our results suggest that Sclareol, by reducing Treg cells frequency and also tumor size can enhance the effect of cancer therapy as an immuno-stimulant.

PMID:
23502334
DOI:
IJIv10i1A2
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Iranian Society of Immunology and Allergy and Shiraz Institute for Cancer
Loading ...
Support Center